Pirantel tablets 250mg №3×1

Name:
Pyrantel tab. 250mg in bl. in pack. No. 3×1
Description:
Tablets are round, flat on both sides, with a dividing risk, sandy-yellow color with a gray-greenish tint with imperceptible specks with an orange taste and smell. Tablets darken under the influence of light, changing color to yellow-brown. The main active ingredientpirantel embonate Form of releaseTablets Dosage250mgSpecial instructionsPyrantel should be used carefully – special medical supervision is necessary for patients: with liver failure, since during treatment the drug can increase the concentration of AspAT, with malnutrition or anemia. Attention In case of enterobiasis, simultaneous treatment of all cohabiting persons should be carried out. It is necessary to strictly adhere to the rules of hygiene. After completion of treatment with Pirantel, 14 days after administration, it is necessary to conduct control parasitological studies. Pregnancy and lactation Controlled studies of the safety of Pyrantel during pregnancy have not been conducted, so the use of the drug during this period is possible only as a last resort, when the intended benefit to the mother outweighs the potential risk to the fetus. Not recommended for women during lactation. If treatment with pyrantel is essential, breast-feeding should be discontinued. Features of influence on the ability to drive a vehicle or potentially dangerous mechanisms In some cases, dizziness may be observed, in this regard, care should be taken when driving vehicles and servicing mechanical equipment. Pharmacological propertiesPharmacodynamicsPyrantel is an effective drug for infection with intestinal roundworms. It acts on the muscles of intestinal nematodes by depolarizing their neuromuscular junction and blocking the action of cholinesterase. Immovable parasites are removed from the intestines due to peristaltic movements. Does not cause migration of helminths, does not have an irritating effect. It acts on mature forms and parasites at an early stage of development and does not affect larvae during their migration in tissues. The drug is used primarily for infections with pinworms (Enterobius vermicularis) and roundworms (Ascaris lumbricoides). Can be used for hookworm infection; has a more effective effect in the treatment of ankylostomiasis than in the treatment of necatoriasis. Pharmacokinetics Absorption Poorly absorbed from the gastrointestinal tract. The plasma concentration of the drug after taking a single dose of 10 mg / kg of body weight is 0.05 – 0.13 μg / ml for 1 to 3 hours. Distribution There are no data on the penetration of the drug through the placenta and into mother’s milk, as well as on the location of the drug in biological tissues and fluids (theoretically, the absorption of the drug is minimal). Metabolism The minimum amount of the drug absorbed in the gastrointestinal tract is partially metabolized in the liver to N-methyl-1,3-propanediamine (0.8-5.6%). Excretion from the body More than 50% of an oral dose is excreted unchanged in the faeces and less than 15% in the urine unchanged or as a metabolite of N-methyl-1,3-propanediamine. Indications for use – enterobiasis – ascariasis – hookworm – necatoriasis Dosage and administration The drug is taken orally, during or after a meal, with water. Before swallowing, the tablet should be thoroughly chewed or crushed. With ascariasis and enterobiasis (as well as with a combination of these diseases), the total therapeutic dose (10 mg / kg / day) is prescribed once. With ankylostomiasis, the daily dose (10 mg / kg / day) is taken 1 time per day for 3 days. In severe forms of necatorosis (massive infestations of Necator americanus), 20 mg/kg/day is prescribed once a day for 2 days or 10 mg/kg/day for 3 days. Interaction with other drugs Do not use simultaneously with piperazine. Joint use has an antagonistic effect. Pirantel may increase the concentration of theophylline in plasma. Contraindications – hypersensitivity to pyrantel or excipients – simultaneous use of piperazine – myasthenia gravis (treatment period) Active substance – pyrantel embonate 720 mg (equivalent to pyrantel 250 mg), excipients: potato starch, povidone, colloidal silicon dioxide, ethylcellulose, magnesium stearate, orange scent. OverdoseSymptoms: visual disturbances, disorientation, dizziness, fainting or dizziness when getting up from a lying or sitting position, excessive sweating, not previously observed feeling of fatigue or weakness, irregular pulse; cramps, trembling and muscle weakness; feeling of exhaustion, asphyxia (suffocation, loss of consciousness). Treatment: symptomatic and supportive (early gastric lavage, airway and breathing support, blood pressure support). There is no specific antidote. Side effects Side effects disappear after treatment is stopped. Rarely (≥1 / 10,000 to <1/1,000) - nausea, vomiting, pain and stomach cramps, lack of appetite, diarrhea, transient increase in aminotransferase activity - headache, dizziness, drowsiness, insomnia, weakness - skin rash With an unknown frequency - urge to defecate - hallucinations, confusion, paresthesia, hearing disorders - fever Storage conditions Store in a dry, dark place at a temperature not exceeding 25°C. Keep out of the reach of children! Buy Pirantel tablets 250mg №3x1 Price for Pirantel tablets 250mg №3x1Instruction for use for Pirantel tablets 250mg №3x1